Td vaccine

Phase 1

UUniversity of Florida

Td vaccine is one of 4 therapeutic programs targeting Recurrent Group 3 Medulloblastoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Recurrent Group 3 MedulloblastomaRecruiting

Recurrent Group 3 MedulloblastomaPhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Recurrent Group 3 Medulloblastoma

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 1

1 2

TTRNA-DC Vaccines With GM-CSF

UUniversity of Florida

Phase 1

1 3

TTRNA-Xalt

UUniversity of Florida

Phase 1

1 4

Td vaccine

UUniversity of Florida

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Recurrent Group 3 Medulloblastoma

NCT06514898

Clinical

Trials by Indication[1]

Recurrent Group 3 Medulloblastoma1 trial

MATCHPOINT - Medulloblastoma Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade

Recruiting·UUniversity of Florida·Phase 1·NCT06514898·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Td vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Td vaccine. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: UUniversity of Florida

Td vaccine

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Recurrent Group 3 Medulloblastoma1 trial

References

Drug Info

Quick Facts

Related News